Eli Lilly and Company's (LLY) Hold (C+) Rating Reaffirmed at Weiss Ratings

Key Points

• Eli Lilly and Company (NYSE: LLY) has received a "hold (C+)" rating reaffirmed by Weiss Ratings, with various other brokerages offering differing views, including upgrades and price target adjustments.
• The company reported a quarterly revenue of $15.56 billion, surpassing analyst estimates, resulting in a 37.6% year-over-year increase in revenue.
• Recent insider trading included purchases by EVP Daniel Skovronsky and Director Jamere Jackson, with a combined investment of approximately $762,312, indicating confidence in the company's stock.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock had its "hold (c+)" rating reaffirmed by analysts at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

A number of other brokerages have also commented on LLY. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Guggenheim restated a "buy" rating and set a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a research note on Friday, October 10th. Finally, Cantor Fitzgerald set a $925.00 target price on shares of Eli Lilly and Company and gave the stock an "overweight" rating in a research note on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $938.61.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $825.86 on Friday. The firm has a market capitalization of $781.65 billion, a PE ratio of 53.98, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The firm has a fifty day simple moving average of $768.01 and a two-hundred day simple moving average of $768.14. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock worth $2,894,841 in the last ninety days. Corporate insiders own 0.13% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently added to or reduced their stakes in the business. Lazard Freres Gestion S.A.S. lifted its holdings in Eli Lilly and Company by 114.3% during the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company's stock valued at $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK lifted its holdings in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock valued at $5,260,000 after purchasing an additional 429 shares during the last quarter. Family CFO Inc purchased a new stake in Eli Lilly and Company during the second quarter valued at about $54,000. Finally, Duquesne Family Office LLC lifted its holdings in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after purchasing an additional 32,640 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.